Affiliation:
1. Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf , 22529 Hamburg , Germany
Abstract
Abstract
Iron is a vital trace element and exerts opposing effects on bone in both iron overload and iron deficiency situations. Remarkably, iron supplementation through intravenous infusion in patients with iron deficiency can also have detrimental effects on bone in special cases. The diverse mechanisms underlying these effects and their manifestations contribute to the complexity of this relationship. Iron overload impacts both bone resorption and formation, accelerating bone resorption while reducing bone formation. These effects primarily result from the direct action of reactive oxygen species (ROS), which influence the proliferation, differentiation, and activity of both osteoclasts and osteoblasts differently. This imbalance favors osteoclasts and inhibits the osteoblasts. Simultaneously, multiple pathways, including bone morphogenic proteins, RANK ligand, and others, contribute to these actions, leading to a reduction in bone mass and an increased susceptibility to fractures. In contrast, iron deficiency induces low bone turnover due to energy and co-factor deficiency, both of which require iron. Anemia increases the risk of fractures in both men and women. This effect occurs at various levels, reducing muscular performance and, on the bone-specific level, decreasing bone mineral density. Crucially, anemia increases the synthesis of the phosphaturic hormone iFGF23, which is subsequently inactivated by cleavage under physiological conditions. Thus, iFGF23 levels and phosphate excretion are not increased. However, in specific cases where anemia has to be managed with intravenous iron treatment, constituents—particularly maltoses—of the iron infusion suppress the cleavage of iFGF23. As a result, patients can experience severe phosphate wasting and, consequently, hypophosphatemic osteomalacia. This condition is often overlooked in clinical practice and is often caused by ferric carboxymaltose. Ending iron infusions or changing the agent, along with phosphate and vitamin D supplementation, can be effective in addressing this issue.
Funder
German Research Foundation
Publisher
Oxford University Press (OUP)
Reference83 articles.
1. Hemoglobin and hip fracture risk in older non-Hispanic white adults;Looker;Osteoporos Int,2014
2. Functional outcomes of anemia in older adults;Chaves;Semin Hematol,2008
3. Not so benign haematology: anaemia of the elderly;Merchant;Br J Haematol,2012
4. Clinical impact and cellular mechanisms of iron overload-associated bone loss;Jeney;Front Pharmacol,2017
5. Shaping the bone through iron and iron-related proteins;Ledesma-Colunga;Semin Hematol,2021